Deborah Kotz is an award-winning health and science journalist currently contributing to Medical Xpress and Newswise, where she reports on precision medicine, genomic research, and biomedical funding landscapes. With a career spanning The Boston Globe, U.S. News & World Report, and other major outlets, she has become a trusted voice in translating complex medical advancements into public knowledge.
Kotz’s work has directly influenced NIH funding priorities and patient advocacy strategies, earning recognition from the National Association of Science Writers and Association of Health Care Journalists. She maintains a rigorous focus on evidence-based reporting, making her pieces essential reading for clinicians and policymakers alike.
Kotz began her career at regional outlets, honing her skills in consumer health reporting. Her early work focused on demystifying healthcare policies and wellness trends, but a shift toward data-driven science journalism marked a turning point. By the mid-2010s, she emerged as a leading voice in translational research coverage, bridging gaps between laboratory discoveries and clinical applications.
This landmark 2025 investigation analyzed data from 800,000 participants across 13 countries, identifying 52 novel genetic markers linked to osteoarthritis progression. Kotz’s reporting highlighted the study’s use of machine learning to prioritize druggable pathways, particularly the role of GPR22 gene variants in cartilage degradation. Her article became a benchmark for explaining polygenic risk scores to lay audiences, featuring interviews with lead researchers at the Broad Institute and Johns Hopkins.
“What sets this study apart isn’t just its scale, but how it redefines osteoarthritis as a cluster of molecular subtypes rather than a single disease of ‘wear and tear.’”
Kotz’s 2025 coverage of Maryland’s 4MLK initiative revealed how cross-institutional collaboration accelerates drug discovery. The piece detailed plans to establish a cryo-EM facility and AI-driven protein folding lab, contextualizing the grant within broader NIH priorities. Her analysis drew praise for clarifying how shared resources reduce duplicative research costs—a rarely explored angle in science funding journalism.
In this 2025 Medical Xpress exclusive, Kotz profiled patients with refractory dermatological conditions, juxtaposing their experiences with emerging biomarker-driven therapies. The article’s strength lay in its methodology: Kotz reviewed 127 clinical trial records and interviewed 14 dermatologists to map the shift from immunosuppressants to targeted biologics. Public response prompted three pharmaceutical firms to issue statements about ongoing pipeline developments.
Kotz prioritizes stories that explain how therapies work at molecular levels. A 2025 pitch about CRISPR-based osteoarthritis interventions succeeded because it included schematics of guide RNA delivery systems. Avoid superficial “breakthrough” claims—she requires evidence of target validation in animal models or Phase Ib trials.
Her coverage of the 4MLK grant exemplifies interest in institutional partnerships. Successful pitches often involve academic researchers working with AI startups or engineering firms. For example, a recent piece on 3D-printed tumor models emerged from a tip about materials scientists collaborating with oncologists.
Kotz frequently spotlights conditions lacking commercial investment. A 2024 series on rare autoimmune diseases led to congressional testimony about NIH budget allocations. Pitches should emphasize public health gaps—such as geographic disparities in clinical trial access—rather than well-trodden topics like diabetes management.
At PressContact, we aim to help you discover the most relevant journalists for your PR efforts. If you're looking to pitch to more journalists who write on Health, here are some other real estate journalist profiles you may find relevant:
